Stock Detail
JOHNSON & JOHNSON
Dow Jones 30 Index
JNJ @ Yahoo Finance | JNJ Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $64.40 | $65.16 | $0.00 | 0.00% | 2.28 | $64.99 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $64.54 | $64.30 | 8.33M | 175.87B | 10.83M | 15.71 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 65.48 | 64.94 | 64.62 | 64.08 | 63.76 |
Stock Profile
Johnson & Johnson engages in the manufacture and sale of various products in the health care field primarily in the United States. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics (MDD). Consumer segment manufactures and markets a range of products used in the baby and child care, skin care, oral and wound care, and women's health care fields, as well as over-the-counter pharmaceutical and nutritional products. These products are marketed primarily to the general public; and sold to wholesalers, and directly to independent and chain retail outlets worldwide. Pharmaceutical segment franchises various products in the anti-fungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic, and urology fields. These products are distributed directly, and through wholesalers and health care professionals for use by prescription by the general public. MDD segment offers a range of products, including wound care and women's health products; minimally invasive surgical products; circulatory disease management products; blood glucose monitoring products; professional diagnostic products; orthopedic joint reconstruction, spinal, and sports medicine products; and disposable contact lenses. These products are distributed directly and through surgical suppliers and other dealers for use by or under the direction of physicians, nurses, therapists, hospitals, diagnostic laboratories, and clinics. Johnson & Johnson has an agreement with Bayer AG to jointly develop and market a compound labelled BAY 59-7939 for the prevention and treatment of thrombosis. The company was founded by Robert Wood Johnson in 1887. Johnson & Johnson is headquartered in New Brunswick, New Jersey.